CJC-1295 vs Kisspeptin-10
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release growth hormone and is almost universally used in combination with a GHRP like Ipamorelin to produce a more physiological GH pulse.
Full profileKisspeptin-10
Kisspeptin-10 is the biologically active 10-amino acid C-terminal fragment of kisspeptin, a neuropeptide that acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R (GPR54) in the hypothalamus, it triggers pulsatile GnRH release, which drives LH, FSH, and downstream testosterone and estrogen production. It is the upstream signal that 'turns on' the reproductive axis — with research applications spanning fertility, hypogonadism, post-cycle therapy support, and age-related hormonal decline.
Full profile| CJC-1295 | Kisspeptin-10 | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC-1295 DAC, CJC-1295 without DAC (Mod GRF 1-29), Modified GRF 1-29 | KP-10, Metastin(112-121), KISS1R agonist |
| Evidence | Research-stage | FDA-approved |
| Dosing range | 100mcg–300mcg mcg, once daily (Mod GRF) or twice weekly (DAC version) | 50mcg–250mcg mcg, 1–2x daily (pulsatile administration is important — avoid continuous infusion) |
| Administration | Subcutaneous injection (most common), Intramuscular injection | Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses) |
| Key side effects | Water retention (especially early in protocol), Tingling or numbness in extremities, Injection site redness, Flushing (transient, shortly after injection) | Generally well-tolerated in clinical trials, Nausea (mild, uncommon), Potential for over-stimulation of the HPG axis at high doses (rarely significant), Theoretical desensitization with continuous (non-pulsatile) dosing |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: CJC-1295 is research-stage, while Kisspeptin-10 is fda-approved.
- Administration: CJC-1295 — Subcutaneous injection (most common), Intramuscular injection; Kisspeptin-10 — Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses).
- Frequency: CJC-1295 is typically once daily (Mod GRF) or twice weekly (DAC version); Kisspeptin-10 is 1–2x daily (pulsatile administration is important — avoid continuous infusion).
- Research depth: this profile cites 2 sources for CJC-1295 vs 3 for Kisspeptin-10.
How each works
CJC-1295
Studies have demonstrated that CJC-1295 significantly increases plasma GH and IGF-1 levels. The DAC (Drug Affinity Complex) version extends the half-life to approximately 6–8 days via albumin binding, while Mod GRF 1-29 has a much shorter half-life (~30 minutes) and is dosed more acutely. Research in adults with GH deficiency has shown improved body composition and metabolic markers.
Kisspeptin-10
Kisspeptin neurons in the arcuate nucleus form the pulse generator for GnRH secretion — without kisspeptin signaling, reproductive function ceases. Human clinical trials confirm that IV kisspeptin-10 produces rapid, dose-dependent LH pulses in both males and females, restoring hormonal function in hypogonadotropic hypogonadism. Kisspeptin-54 (the longer form) has been studied in human fertility treatments with successful outcomes. Unlike direct LH/FSH administration, kisspeptin works upstream at the hypothalamus, preserving the natural pulsatile release pattern and avoiding receptor desensitization associated with continuous GnRH agonists.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.